Patents by Inventor Kenneth Mark Parnell

Kenneth Mark Parnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MCT4 INHIBITORS FOR TREATING DISEASE
    Publication number: 20240101518
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selevtivity for MCT4 over MCT1.
    Type: Application
    Filed: June 19, 2023
    Publication date: March 28, 2024
    Inventors: Kenneth Mark PARNELL, John MCCALL
  • MCT4 inhibitors for treating disease
    Patent number: 11724989
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: August 15, 2023
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall
  • MCT4 INHIBITORS FOR TREATING DISEASE
    Publication number: 20220251045
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.
    Type: Application
    Filed: September 22, 2021
    Publication date: August 11, 2022
    Inventors: Kenneth Mark PARNELL, John MCCALL
  • HETEROCYCLIC INHIBITORS OF MCT4
    Publication number: 20220251047
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 11, 2022
    Inventors: Kenneth Mark PARNELL, John MCCALL, Donna ROMERO
  • Heterocyclic inhibitors of MCT4
    Patent number: 11292767
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: April 5, 2022
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall, Donna Romero
  • MCT4 inhibitors for treating disease
    Patent number: 11155522
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: October 26, 2021
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall
  • MCT4 INHIBITORS FOR TREATING DISEASE
    Publication number: 20210009524
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Inventors: Kenneth Mark PARNELL, John MCCALL
  • PKM2 MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20210002233
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: July 15, 2020
    Publication date: January 7, 2021
    Inventors: Koc-Kan HO, Yong XU, Michael David SAUNDERS, Xiaohui LIU, Scott Albert PEARCE, Kevin Bret WRIGHT, Jason Marc FOULKS, Kenneth Mark PARNELL, Steven Brian KANNER, David Lee VOLLMER, Jihua LIU
  • PKM2 modulators and methods for their use
    Patent number: 10766865
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 8, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • PKM2 MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20200109120
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: September 26, 2019
    Publication date: April 9, 2020
    Inventors: Koc-Kan HO, Yong XU, Michael David SAUNDERS, Xiaohui LIU, Scott Albert PEARCE, Kevin Bret WRIGHT, Jason Marc FOULKS, Kenneth Mark PARNELL, Steven Brian KANNER, David Lee VOLLMER, Jihua LIU
  • PKM2 modulators and methods for their use
    Patent number: 10472328
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 12, 2019
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • PKM2 MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20190119219
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 25, 2019
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • MCT4 INHIBITORS FOR TREATING DISEASE
    Publication number: 20190112274
    Abstract: Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventors: Kenneth Mark PARNELL, John MCCALL
  • HETEROCYCLIC INHIBITORS OF MCT4
    Publication number: 20190112275
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventors: Kenneth Mark PARNELL, John MCCALL, Donna ROMERO
  • Heterocyclic inhibitors of MCT4
    Patent number: 10214492
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: February 26, 2019
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall, Donna Romero
  • PKM2 modulators and methods for their use
    Patent number: 10207996
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: February 19, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • MCT4 inhibitors for treating disease
    Patent number: 10202350
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: February 12, 2019
    Assignee: Vettore, LLC
    Inventors: Kenneth Mark Parnell, John McCall
  • HETEROCYCLIC INHIBITORS OF MCT4
    Publication number: 20180162822
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 14, 2018
    Inventors: Kenneth Mark PARNELL, John MCCALL, Donna ROMERO
  • PKM2 MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20170015631
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: June 15, 2016
    Publication date: January 19, 2017
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • MCT4 INHIBITORS FOR TREATING DISEASE
    Publication number: 20160362378
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 15, 2016
    Inventors: Kenneth Mark Parnell, John McCall